Btnl9-flox Mouse
Common Name
Btnl9-flox
제품 ID
S-CKO-07946
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-237754-Btnl9-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Btnl9-flox Mouse (카탈로그 번호 S-CKO-07946)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Btnl9-flox
품종 계통계통 ID
CKOCMP-237754-Btnl9-B6J-VA
유전자명
제품 ID
S-CKO-07946
유전자 별칭
Btn3, B430208I01, D330012D11Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 11
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000046522
NCBI 전사체 ID
NM_172793
타겟 영역
Exon 2~4
유효 영역 크기
~5.8 kb
유전자 연구 개요
Btnl9, or butyrophilin-like protein 9, is a member of the immunoglobulin families. It has been implicated in immune-related and cancer-related pathways [1]. Functional enrichment analyses suggest its involvement in various biological processes relevant to disease mechanisms.
In multiple cancer types, studies have shown significant associations. In thyroid cancer (THCA), BTNL9 expression is down-regulated, related to tumor stages, immune cell infiltrations, and prognosis, with lower expression associated with a poorer progression-free interval (PFI) [1]. In breast cancer, its down-regulation is common, and ectopic expression inhibits cell proliferation, colony formation, and metastasis, while inducing apoptosis, acting via the P53/CDC25C and P53/GADD45 pathways [2]. In non-small-cell lung cancer, lncRNA CALML3-AS1 drives cancer progression by epigenetically repressing BTNL9 [3]. In uveal melanoma, high BTNL9 expression is associated with a favorable prognosis, and it can suppress invasion [4]. In lung adenocarcinoma, its down-regulation is linked to a poor overall survival probability, and it is positively correlated with immune-related scores and immune cell infiltration levels [5]. In pancreatic cancer, decreased BTNL9 expression is associated with a reduced survival rate [6]. In BRAF-mutated peritoneal metastasis from colorectal cancer, increased expression of BTNL9 is observed [7].
In idiopathic pulmonary fibrosis, BTNL9 is down-regulated, and it may have a protective effect by inhibiting extracellular matrix production and promoting wound repair [8]. In ALS, a negative correlation between BTNL9 and ALS risk was identified through Mendelian randomization analysis [9].
In conclusion, BTNL9 appears to play diverse roles in multiple diseases, especially in various cancers and potentially in neurodegenerative and fibrotic diseases. Its down-regulation is often associated with poor prognosis in cancer, and it is involved in regulating cell proliferation, metastasis, and immune-related processes. These findings from different disease-based studies contribute to understanding its biological functions and potential as a biomarker or therapeutic target.
References:
1. Zhang, Luyao, Yu, Shuang, Hong, Shubin, Li, Yanbing, Xiao, Haipeng. 2023. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer. In BMC medical genomics, 16, 234. doi:10.1186/s12920-023-01676-8. https://pubmed.ncbi.nlm.nih.gov/37798795/
2. Mo, Qingfan, Xu, Ke, Luo, Chenghao, Wang, Long, Ren, Guosheng. 2021. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. In Biochemical and biophysical research communications, 553, 17-24. doi:10.1016/j.bbrc.2021.03.022. https://pubmed.ncbi.nlm.nih.gov/33756341/
3. Zhang, Heng, Wang, Shao-Qiang, Zhu, Jie-Bo, Duan, Chao-Jun, Zhang, Chun-Fang. 2023. LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression. In Cancer gene therapy, 30, 1649-1662. doi:10.1038/s41417-023-00670-7. https://pubmed.ncbi.nlm.nih.gov/37884580/
4. Jiang, Zhongming, Liu, Fei. 2019. Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma. In Medical science monitor : international medical journal of experimental and clinical research, 25, 3190-3198. doi:10.12659/MSM.914074. https://pubmed.ncbi.nlm.nih.gov/31039142/
5. Ma, Weishuang, Liang, Jiaming, Mo, Junjian, Tian, Dongbo, Chen, Zisheng. 2021. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. In BMC cancer, 21, 1096. doi:10.1186/s12885-021-08790-9. https://pubmed.ncbi.nlm.nih.gov/34635082/
6. Khojasteh-Leylakoohi, Fatemeh, Mohit, Reza, Khalili-Tanha, Nima, Batra, Jyotsna, Avan, Amir. 2023. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. In Scientific reports, 13, 16678. doi:10.1038/s41598-023-42928-y. https://pubmed.ncbi.nlm.nih.gov/37794108/
7. Lund-Andersen, Christin, Torgunrud, Annette, Kanduri, Chakravarthi, Larsen, Stein G, Flatmark, Kjersti. 2024. Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. In Journal of translational medicine, 22, 646. doi:10.1186/s12967-024-05467-2. https://pubmed.ncbi.nlm.nih.gov/38982444/
8. Zheng, Peiyan, Sun, Shixue, Wang, Jingxian, Zhang, Xiaohua Douglas, Sun, Baoqing. 2022. Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis. In Cellular and molecular life sciences : CMLS, 79, 66. doi:10.1007/s00018-021-04094-0. https://pubmed.ncbi.nlm.nih.gov/35015148/
9. Lu, Chuan, Huang, Xiao-Xiao, Huang, Ming, Liu, Chaoning, Xu, Jianwen. 2025. Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses. In BMC neurology, 25, 82. doi:10.1186/s12883-025-04091-x. https://pubmed.ncbi.nlm.nih.gov/40033250/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
